IRadimed Corporation
IRMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.08 | 1.04 | 0.81 | 0.10 |
| FCF Yield | 2.53% | 0.91% | 2.30% | 1.84% |
| EV / EBITDA | 28.30 | 26.47 | 18.39 | 45.53 |
| Quality | ||||
| ROIC | 19.31% | 20.66% | 16.12% | 12.15% |
| Gross Margin | 76.94% | 76.50% | 77.45% | 76.65% |
| Cash Conversion Ratio | 1.33 | 0.78 | 0.78 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.17% | 16.17% | 18.89% | 2.78% |
| Free Cash Flow Growth | 222.83% | -33.18% | -22.33% | 102.99% |
| Safety | ||||
| Net Debt / EBITDA | -2.29 | -2.29 | -3.42 | -5.30 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.62 | 1.20 | 2.24 | 2.27 |
| Cash Conversion Cycle | 236.39 | 327.85 | 199.30 | 176.30 |